Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。